Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple Finger-Prick replace the dreaded diabetes test for kids?

NCT ID NCT06815081

Diagnosis Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study from the University of Oxford is testing whether a finger-prick blood test, done at home, can replace the standard oral glucose tolerance test (OGTT) for diagnosing type 1 and type 2 diabetes in children and young people. The standard OGTT requires a vein drip and multiple blood samples over hours, which is uncomfortable. The researchers will also explore using a continuous glucose monitor as an alternative. The study involves 135 participants and aims to see if the home test is accurate and acceptable for routine care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
finger-prick glucose test and continuous glucose monitor
What this could lead to
If successful, this could make diabetes testing easier and more comfortable for children, allowing early diagnosis at home instead of in a clinic.
What could go wrong
This is a small, early feasibility study (135 participants) focused on accuracy and acceptability, not on treatment. The home test may not match the precision of the standard venous test.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 135 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Cohort 1 - Children \< 18 years of age. To get a spread of glucose values, we will aim to recruit approximately equal numbers of participants with normoglycaemia, dysglycaemia and hyperglycaemia. Cohort 1 CGM sub-study - Children \< 18 years of age, who have T1D stage 1, 2 or 3 and undergoing an OGTT in cohort 1.This sub-study will be additional and optional to cohort 1. Cohort 2 - Children \< 18 years of age, who are identified as having stage 1, 2 or 3 T1D will be invited to take part in an OGTT at home. Cohort 3 - Children \< 18 years of age, who are identified as having pre-T2D. Qualitative sub-study - Young people ≥ 15 years old with T1D stage 1, 2 or recent stage 3 (up to 12 months), who have been involved in metabolic follow-up, will be invited to take part. Parents of a child (of any age) with T1D stage 1, 2 or recent stage 3 will also be invited. Healthcare professionals involved in delivering metabolic follow-up for children with diabetes antibodies will also be invited.

Ages

Up to 17 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: Cohort 1 * Willing and able to give informed consent for participation, or assent with parental consent * Aged \< 18 years old * Able to consume oral glucose drink within 10 minutes * Undergoing an OGTT, or consent to have one Cohort 2 * Positive for two or more islet autoantibodies at any time * Willing and able to give informed consent for participation, or assent with parental consent * Aged \< 18 years old * Able to consume oral glucose drink within 10 minutes CGM sub-study * Willing and able to give informed consent for participation, or assent with parental consent * Aged \< 18 years old * Able to consume oral glucose drink within 10 minutes * Confirmed to have stage 1, 2 or 3 T1D * Participation in Cohort 1 Qualitative sub-study * Willing and able to give informed consent for participation, or assent with parental consent Then EITHER * A young person positive for two or more islet autoantibodies (15 years old and above) at any time, or parent of a young person who has experienced a metabolic test e.g. OGTT OR * A healthcare professional involved in delivering metabolic testing Cohort 3 * Prediabetes diagnosis as above * Willing and able to give informed consent for participation, or assent with parental consent * Aged \< 18 years old * Able to consume oral glucose drink within 10 minutes Exclusion Criteria: Cohort 1 * Any known haemoglobinopathy * Cystic fibrosis related diabetes * Non-English speaker Cohort 2 * Any known haemoglobinopathy * Known clinical diabetes and on treatment * Non-English speaker * No recent weight available (within 3 months of study visit) and unable to obtain new weight measurement CGM sub-study * Any known haemoglobinopathy * Cystic fibrosis related diabetes * Non-English speaker * Any active skin issue which would prevent the use of a CGM device Qualitative sub-study • Non-English speaker Cohort 3 * Known clinical diabetes and on treatment * Non-English speaker * No recent weight available (within 3 months of study visit) and unable to obtain new weight measurement

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prediabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prediabetes syndrome type 1 diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 1 diabetes (T1D) Type 2 diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • John Radcliffe Hospital

    RECRUITING

    Oxford, OX3 9DU, United Kingdom

  • Noah's Ark Childrens Hospital for Wales

    RECRUITING

    Cardiff, CF14 4XW, United Kingdom

  • Nottingham Childrens Hospital

    RECRUITING

    Nottingham, NG7 2UH, United Kingdom

  • Royal London Barts Health NHS Trust

    RECRUITING

    London, E1 1FR, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.